Katharine Grimmer

774 total citations · 3 hit papers
10 papers, 595 citations indexed

About

Katharine Grimmer is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Cancer Research. According to data from OpenAlex, Katharine Grimmer has authored 10 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Epidemiology and 4 papers in Cancer Research. Recurrent topics in Katharine Grimmer's work include Liver Disease Diagnosis and Treatment (4 papers), Cancer, Lipids, and Metabolism (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Katharine Grimmer is often cited by papers focused on Liver Disease Diagnosis and Treatment (4 papers), Cancer, Lipids, and Metabolism (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Katharine Grimmer collaborates with scholars based in United States, Hong Kong and France. Katharine Grimmer's co-authors include Marie O’Farrell, William McCulloch, Hartmut Koeppen, Anan Chuntharapai, Avi Ashkenazi, Kurt A. Schroeder, Scot A. Marsters, George Kemble, Stephen A. Harrison and Rohit Loomba and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and Cancer Research.

In The Last Decade

Katharine Grimmer

9 papers receiving 589 citations

Hit Papers

First-in-human study of t... 2021 2026 2022 2024 2021 2021 2024 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
    2021 192 citations Gerald S. Falchook, Jeffrey R. Infante et al. EClinicalMedicine profile →
  2. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
    2021 163 citations Rohit Loomba, Rizwana Mohseni et al. Gastroenterology profile →
  3. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
    2024 44 citations Rohit Loomba, Pierre Bédossa et al. ˜The œLancet. Gastroenterology & hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katharine Grimmer United States 6 339 250 192 92 83 10 595
I‐Hsiao Chung Taiwan 16 446 1.3× 373 1.5× 63 0.3× 49 0.5× 75 0.9× 18 644
Ninghua Yao China 13 331 1.0× 266 1.1× 51 0.3× 68 0.7× 117 1.4× 43 516
Zhe Yang China 15 407 1.2× 280 1.1× 74 0.4× 81 0.9× 135 1.6× 42 656
Quentin Bayard France 9 302 0.9× 245 1.0× 162 0.8× 26 0.3× 105 1.3× 13 630
Chen‐Hong Ding China 10 386 1.1× 224 0.9× 99 0.5× 61 0.7× 71 0.9× 21 533
Judit Peix Spain 7 307 0.9× 240 1.0× 133 0.7× 58 0.6× 157 1.9× 10 657
Takaaki Imamura Japan 12 351 1.0× 182 0.7× 126 0.7× 54 0.6× 181 2.2× 24 647
Guang-Ang Tian China 13 324 1.0× 180 0.7× 53 0.3× 129 1.4× 166 2.0× 20 582
Sara Torrecilla United States 6 252 0.7× 206 0.8× 82 0.4× 55 0.6× 121 1.5× 10 512
Yifei Cheng China 12 285 0.8× 200 0.8× 101 0.5× 49 0.5× 110 1.3× 39 566

Countries citing papers authored by Katharine Grimmer

Since Specialization
Citations

This map shows the geographic impact of Katharine Grimmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katharine Grimmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katharine Grimmer more than expected).

Fields of papers citing papers by Katharine Grimmer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katharine Grimmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katharine Grimmer. The network helps show where Katharine Grimmer may publish in the future.

Co-authorship network of co-authors of Katharine Grimmer

This figure shows the co-authorship network connecting the top 25 collaborators of Katharine Grimmer. A scholar is included among the top collaborators of Katharine Grimmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katharine Grimmer. Katharine Grimmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
2.
Loomba, Rohit, Pierre Bédossa, Katharine Grimmer, et al.. (2024). Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. ˜The œLancet. Gastroenterology & hepatology. 9(12). 1090–1100. 44 indexed citations breakdown →
3.
4.
5.
Falchook, Gerald S., Jeffrey R. Infante, Hendrik‐Tobias Arkenau, et al.. (2021). First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 34. 100797–100797. 192 indexed citations breakdown →
6.
Loomba, Rohit, Rizwana Mohseni, Kathryn Jean Lucas, et al.. (2021). TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 161(5). 1475–1486. 163 indexed citations breakdown →
7.
8.
O’Farrell, Marie, Katharine Grimmer, R. Webster Crowley, et al.. (2016). Abstract LB-214: FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study. Cancer Research. 76(14_Supplement). LB–214. 8 indexed citations
9.
Chuntharapai, Anan, Katharine Grimmer, Kurt A. Schroeder, et al.. (2001). Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4. The Journal of Immunology. 166(8). 4891–4898. 167 indexed citations
10.
Grimmer, Katharine, et al.. (2000). Early phase collagen synthesis in lungs of rats exposed to bleomycin. Toxicology. 147(1). 1–13. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by I‐Hsiao Chung Breakdown of academic impact, for papers by Ninghua Yao Breakdown of academic impact, for papers by Zhe Yang Breakdown of academic impact, for papers by Quentin Bayard Breakdown of academic impact, for papers by Chen‐Hong Ding Breakdown of academic impact, for papers by Judit Peix Breakdown of academic impact, for papers by Takaaki Imamura Breakdown of academic impact, for papers by Guang-Ang Tian Breakdown of academic impact, for papers by Sara Torrecilla Breakdown of academic impact, for papers by Yifei Cheng
Rankless by CCL
2026